产品
编 号：F272200
分子式：C20H20N2O3S
分子量：368.45
分子式：C20H20N2O3S
分子量：368.45
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 2131803-90-0
产品详情
生物活性：
WYC-209, a synthetic retinoid, is a retinoic acid receptor (RAR) agonist. WYC-209 induces apoptosis primarily via the caspase 3 pathway (IC50=0.19?μM for inmalignant murine melanoma TRCs), and has long-term effects with little toxicity.
体内研究：
WYC-209 (0.022-0.22 mg/kg; i.v.; once every two days for 25 days) inhibits tumor metastasis in C57BL/6 mice bearing lung metastases.Animal Model:Female immune-competent C57BL/6 mice
Dosage:0.022, 0.22?mg/kg
Administration:Intravenous injection; once every two days for 25 days
Result:Four out of eight mice formed lung metastases at dose of 0.022?mg?/kg, only one out of eight mice formed lung metastases at dose of 0.22?mg/kg.
体外研究：
WYC-209 (10 μM; 24 hours) is able to inhibit and block growth of TRCs of human tumor cells in culture with a long-lasting effect.
WYC-209, a synthetic retinoid, is a retinoic acid receptor (RAR) agonist. WYC-209 induces apoptosis primarily via the caspase 3 pathway (IC50=0.19?μM for inmalignant murine melanoma TRCs), and has long-term effects with little toxicity.
体内研究：
WYC-209 (0.022-0.22 mg/kg; i.v.; once every two days for 25 days) inhibits tumor metastasis in C57BL/6 mice bearing lung metastases.Animal Model:Female immune-competent C57BL/6 mice
Dosage:0.022, 0.22?mg/kg
Administration:Intravenous injection; once every two days for 25 days
Result:Four out of eight mice formed lung metastases at dose of 0.022?mg?/kg, only one out of eight mice formed lung metastases at dose of 0.22?mg/kg.
体外研究：
WYC-209 (10 μM; 24 hours) is able to inhibit and block growth of TRCs of human tumor cells in culture with a long-lasting effect.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备